SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Paul Kligfield, Fabio Badilini, Ian Rowlandson, Joel Xue, Elaine Clark, Brian Devine, Peter Macfarlane, Johan de Bie, David Mortara, Saeed Babaeizadeh, Richard Gregg, Eric D. Helfenbein, Cynthia L. Green, Comparison of automated measurements of electrocardiographic intervals and durations by computer-based algorithms of digital electrocardiographs, American Heart Journal, 2014, 167, 2, 150

    CrossRef

  2. 2
    Haitao Yuan, Jing Zhao, Jiabin Guo, Ruiqin Wu, Li He, Yaxiong Cui, Min Feng, Tingfen Zhang, Mingyue Hou, Qian Guo, Lijun Zhang, Li Jia, Chang Huang, Lin Ye, Shuangqing Peng, Comparison of freely-moving telemetry Chinese Miniature Experiment Pigs (CMEPs) to beagle dogs in cardiovascular safety pharmacology studies, Journal of Pharmacological and Toxicological Methods, 2014, 70, 1, 19

    CrossRef

  3. 3
    Robert C. Shumaker, Meijian Zhou, Min Ren, Jean Fan, Gresel Martinez, Jagadeesh Aluri, Borje Darpo, Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers, Cancer Chemotherapy and Pharmacology, 2014, 73, 6, 1109

    CrossRef

  4. 4
    Nicolas Lindegger, Patricia N. Sidharta, Kathrin Reseski, Jasper Dingemanse, Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects, Pulmonary Pharmacology & Therapeutics, 2014, 29, 1, 41

    CrossRef

  5. 5
    Shadi Asadollahi, Kamran Heidari, Reza Vafaee, Mohammad Mahdi Forouzanfar, Afshin Amini, Ali Shahrami, Promethazine Plus Sumatriptan in the Treatment of Migraine: A Randomized Clinical Trial, Headache: The Journal of Head and Face Pain, 2014, 54, 1
  6. 6
    Innocent Monya-Tambi, Ricardo Castillo, Asma Syed, QTc prolongation and ventricular premature complexes secondary to insulin-induced hypoglycemia in a diabetic patient, Cardiovascular Endocrinology, 2014, 3, 2, 79

    CrossRef

  7. 7
    Anne-Françoise Aubry, Lisa J Christopher, Jian Wang, Mingshe Zhu, Giridhar Tirucherai, Mark E Arnold, Reflecting on a decade of metabolite screening and monitoring, Bioanalysis, 2014, 6, 5, 651

    CrossRef

  8. 8
    S. Fanoe, D. Kristensen, A. Fink-Jensen, H. K. Jensen, E. Toft, J. Nielsen, P. Videbech, S. Pehrson, H. Bundgaard, Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management, European Heart Journal, 2014, 35, 20, 1306

    CrossRef

  9. 9
    Pieter-Jan de Kam, Jacqueline van Kuijk, Otilia Lillin, Teun Post, Torben Thomsen, The Effect of Therapeutic and Supratherapeutic Oral Doses of Nomegestrol Acetate (NOMAC)/17β-Estradiol (E2) on QTcF Intervals in Healthy Women: Results from a Randomized, Double-Blind, Placebo- and Positive-Controlled Trial, Clinical Drug Investigation, 2014, 34, 6, 413

    CrossRef

  10. 10
    Steven G. Potkin, Sheldon Preskorn, Marla Hochfeld, Xiangyi Meng, A Thorough QTc Study of 3 Doses of Iloperidone Including Metabolic Inhibition Via CYP2D6 and/or CYP3A4 and a Comparison to Quetiapine and Ziprasidone, Journal of Clinical Psychopharmacology, 2013, 33, 1, 3

    CrossRef

  11. 11
    Rashmi R. Shah, Joel Morganroth, Devron R. Shah, Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval), Drug Safety, 2013, 36, 5, 295

    CrossRef

  12. 12
    Mitesh J. Borad, Arundhati D. Soman, Martin Benjamin, Daniel Casa, Waibhav D. Tembe, Barbara F. Piper, Ramesh Ramanathan, Raoul Tibes, Gayle Jameson, Karen Ansaldo, Daniel D. Von Hoff, Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials, Investigational New Drugs, 2013, 31, 4, 1056

    CrossRef

  13. 13
    Ying Wang, George G. Nomikos, Aziz Karim, Melvin Munsaka, Michael Serenko, Maggie Liosatos, Stuart Harris, Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study, Clinical Pharmacology in Drug Development, 2013, 2, 4
  14. 14
    Christer Gottfridsson, Glenn Carlson, Jaakko Lappalainen, Mark Sostek, Evaluation of the Effect of Naloxegol on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT/QTc Study in Healthy Volunteers, Clinical Therapeutics, 2013, 35, 12, 1876

    CrossRef

  15. 15
    Tsuyoshi SHIGA, Important Drug-Drug Interactions in the Clinical Setting, Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 6, 490

    CrossRef

  16. 16
    Beatriz Trenor, Julio Gomis-Tena, Karen Cardona, Lucia Romero, Sridharan Rajamani, Luiz Belardinelli, Wayne R Giles, Javier Saiz, In silico assessment of drug safety in human heart applied to late sodium current blockers, Channels, 2013, 7, 4, 249

    CrossRef

  17. 17
    W. Victor R. Vieweg, Mehrul Hasnain, Jules C. Hancox, Adrian Baranchuk, Geneviève C. Digby, Christopher Kogut, Ericka L. Breden Crouse, Jayanthi N. Koneru, Anand Deshmukh, Ananda K. Pandurangi, Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports, Psychopharmacology, 2013, 228, 4, 515

    CrossRef

  18. 18
    Arne Ring, Tobias Brand, Sreeraj Macha, Kerstin Breithaupt-Groegler, Gudrun Simons, Beate Walter, Hans J Woerle, Uli C Broedl, The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study, Cardiovascular Diabetology, 2013, 12, 1, 70

    CrossRef

  19. 19
    Joanna Parkinson, Sandra A.G. Visser, Philip Jarvis, Chris Pollard, Jean-Pierre Valentin, James W.T. Yates, Lorna Ewart, Translational pharmacokinetic–pharmacodynamic modeling of QTc effects in dog and human, Journal of Pharmacological and Toxicological Methods, 2013, 68, 3, 357

    CrossRef

  20. 20
    Carlos Iribarren, Alfred D. Round, Jonathan A. Peng, Meng Lu, Jonathan G. Zaroff, Taylor J. Holve, Amit Prasad, Paul Stang, Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study, Pharmacoepidemiology and Drug Safety, 2013, 22, 11
  21. 21
    Richat Abbas, Bruce A. Hug, Cathie Leister, Daryl Sonnichsen, A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects, International Journal of Cancer, 2012, 131, 3
  22. 22
    Joseph P. Boni, Cathie Leister, Bruce Hug, Jaime Burns, Daryl Sonnichsen, A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults, Cancer Chemotherapy and Pharmacology, 2012, 69, 6, 1433

    CrossRef

  23. 23
    Richat Abbas, Cathie Leister, Myriam El Gaaloul, Stephan Chalon, Daryl Sonnichsen, Ascending Single-Dose Study of the Safety Profile, Tolerability, and Pharmacokinetics of Bosutinib Coadministered With Ketoconazole to Healthy Adult Subjects, Clinical Therapeutics, 2012, 34, 9, 2011

    CrossRef

  24. 24
    James M. Ritter, Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP), British Journal of Clinical Pharmacology, 2012, 73, 3
  25. 25
    Rashmi R. Shah, Joel Morganroth, Early Investigation of QTc Liability, Drug Safety, 2012, 35, 9, 695

    CrossRef

  26. 26
    Rashmi R. Shah, Joel Morganroth, Early Investigation of QTc Liability, Drug Safety, 2012, 35, 9, 695

    CrossRef

  27. 27
    A. W. Tolcher, K. N. Chi, N. D. Shore, R. Pili, A. Molina, M. Acharya, T. Kheoh, J. J. Jiao, M. Gonzalez, A. Trinh, C. Pankras, N. Tran, Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer, Cancer Chemotherapy and Pharmacology, 2012, 70, 2, 305

    CrossRef

  28. 28
    R. Thertulien, G. M. Manikhas, L. Y. Dirix, J. B. Vermorken, K. Park, M. M. Jain, J. J. Jiao, J. Natarajan, T. Parekh, P. Zannikos, A. P. Staddon, Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies, Cancer Chemotherapy and Pharmacology, 2012, 69, 2, 341

    CrossRef

  29. 29
    Benoît Tyl, Meriam Kabbaj, Sara Azzam, Ander Sologuren, Román Valiente, Elizabeth Reinbolt, Kathryn Roupe, Nathalie Blanco, William Wheeler, Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT-Concentration Analysis, The Journal of Clinical Pharmacology, 2012, 52, 6
  30. You have free access to this content30
    Xuexin He, Su Li, He Huang, Zhiming Li, Likun Chen, Sheng Ye, Jiajia Huang, Jing Zhan, Tongyu Lin, A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours, British Journal of Clinical Pharmacology, 2011, 71, 6
  31. 31
    Liliana Sintra Grilo, Pierre-Alain Carrupt, Hugues Abriel, Antoine Daina, Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization, European Journal of Medicinal Chemistry, 2011, 46, 8, 3486

    CrossRef

  32. 32
    Yeong-Liang Lin, Chia-Ling Hsiao, Ya-Chi Wu, Mei-Fen Kung, Electrophysiologic, Pharmacokinetic, and Pharmacodynamic Values Indicating a Higher Risk of Torsades de Pointes, The Journal of Clinical Pharmacology, 2011, 51, 6
  33. 33
    Kenny J. Watson, William P. Gorczyca, John Umland, Ying Zhang, Xian Chen, Sunny Z. Sun, Bernard Fermini, Mark Holbrook, Piet H. Van Der Graaf, Pharmacokinetic–pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys, Journal of Pharmacological and Toxicological Methods, 2011, 63, 3, 304

    CrossRef

  34. 34
    Guyan Liang, Yong Mi Choi-Sledeski, Gregory B. Poli, Xin Chen, Anne Minnich, Qingping Wang, Joseph Tsay, Keith Sides, Roy J. Vaz, Structure-based design, synthesis, and profiling of a β-tryptase inhibitor with a spiro-piperidineamide scaffold, benzylamine P1 group, and a substituted indole P4 group, MedChemComm, 2011, 2, 8, 794

    CrossRef

  35. 35
    Simon Authier, Michael K. Pugsley, Eric Troncy, Michael J. Curtis, Arrhythmogenic liability screening in cardiovascular safety pharmacology: Commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies, Journal of Pharmacological and Toxicological Methods, 2010, 62, 2, 83

    CrossRef

  36. 36
    Rashmi R. Shah, Preben Bjerregaard, Ihor Gussak, Drug-induced QT interval shortening: an emerging component in integrated assessment of cardiac safety of drugs, Journal of Electrocardiology, 2010, 43, 5, 386

    CrossRef

  37. 37
    Rashmi R Shah, Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives, British Journal of Pharmacology, 2010, 159, 1
  38. 38
    Gianluca Airoldi, Efficacia e tossicità della terapia farmacologica per il controllo del paziente acutamente agitato (I parte), Italian Journal of Medicine, 2010, 4, 2, 127

    CrossRef

  39. 39
    Gianluca Airoldi, Efficacia e tossicità della terapia farmacologica per il controllo del paziente acutamente agitato (II parte), Italian Journal of Medicine, 2010, 4, 3, 192

    CrossRef

  40. 40
    Eun-Yong Chung, Hea-Young Cho, Ji-Hun Cha, Kyoung-Jin Kwon, Seol-Hee Jeon, Su-Hyun Jo, Eun-Jung Kim, Hye-Soo Kim, Hye-Ju Chung, Inhibitory Effect of Nicardipine on hERG Channel, Biomolecules and Therapeutics, 2010, 18, 4, 448

    CrossRef

  41. 41
    Brendan M. Johnson, Laurel M. Adams, Ke Zhang, Shelby D. Gainer, Lyndon C. Kirby, Robert A. Blum, Glen Apseloff, Royce A. Morrison, MD, Peter F. Lebowitz, Ketoconazole and Rifampin Significantly Affect the Pharmacokinetics, But Not the Safety or QTc Interval, of Casopitant, a Neurokinin-1 Receptor Antagonist, The Journal of Clinical Pharmacology, 2010, 50, 8
  42. 42
    Borje Darpo, Sun K. Lee, Thomas E. Moon, Nancy Sills, Jay W. Mason, Oritavancin, a New Lipoglycopeptide Antibiotic: Results From a Thorough QT Study, The Journal of Clinical Pharmacology, 2010, 50, 8
  43. 43
    Vaibhav Salvi, Dilip R Karnad, Gopi Krishna Panicker, Snehal Kothari, Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development, British Journal of Pharmacology, 2010, 159, 1
  44. 44
    William M. Sage, Will Embryonic Stem Cells Change Health Policy?, The Journal of Law, Medicine & Ethics, 2010, 38, 2
  45. 45
    Takao Katoh, Clinical Background and Evaluation of Drug-Induced Prolongation of QT Interval, Journal of Arrhythmia, 2009, 25, 2, 56

    CrossRef

  46. 46
    Takao Katoh, Clinical Background and Evaluation of Drug-Induced Prolongation of QT Interval, Journal of Arrhythmia, 2009, 25, 2, 56

    CrossRef

  47. 47
    Takao Katoh, Clinical background of drug-induced long QT syndrome, Folia Pharmacologica Japonica, 2009, 133, 1, 19

    CrossRef

  48. 48
    Robert H. Howland, Clinical Implications of Chirality and Stereochemistry in Psychopharmacology, Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 8, 17

    CrossRef

  49. 49
    Benoît Tyl, Meriam Kabbaj, Basmah Fassi, Patrick Jode, William Wheeler, Comparison of Semiautomated and Fully Automated Methods for QT Measurement During a Thorough QT/QTc Study: Variability and Sample Size Considerations, The Journal of Clinical Pharmacology, 2009, 49, 8
  50. 50
    Wonjin Lee, Young Hwan Kim, Kwang-Rae Cho, Sang-Eun Lee, Jeong Han Lee, Se Hun Lim, Kun Moo Lee, Soon Ho Cheong, Young-Kyun Choe, Young-Jae Kim, Chee-Mahn Shin, Effect of remifentanil on QT dispersion, Korean Journal of Anesthesiology, 2009, 57, 6, 737

    CrossRef

  51. 51
    Yeong-Liang Lin, Ya-Chi Wu, Guei-Feng Tsai, Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone—A claims database approach, Pharmacoepidemiology and Drug Safety, 2009, 18, 9
  52. 52
    Yeong-Liang Lin, Mei-Fen Kung, Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes, Pharmacoepidemiology and Drug Safety, 2009, 18, 3
  53. 53
    Claus Graff, Jørgen Matz, Ellen B. Christensen, Mads P. Andersen, Jørgen K. Kanters, Egon Toft, Steen Pehrson, Thomas B. Hardahl, Jimmi Nielsen, Johannes J. Struijk, Quantitative Analysis of T-wave Morphology Increases Confidence in Drug-Induced Cardiac Repolarization Abnormalities: Evidence From the Investigational IKr Inhibitor Lu 35–138, The Journal of Clinical Pharmacology, 2009, 49, 11
  54. 54
    D. J. Chang, T. D. Kweon, S. B. Nam, J. S. Lee, C. S. Shin, C. H. Park, D. W. Han, Effects of fentanyl pretreatment on the QTc interval during propofol induction, Anaesthesia, 2008, 63, 10
  55. 55
    Hiroshi Goto, Noritaka Mamorita, Noriaki Ikeda, Hideo Miyahara, Estimation of the upper limit of the reference value of the QT interval in rest electrocardiograms in healthy young Japanese men using the bootstrap method, Journal of Electrocardiology, 2008, 41, 6, 703.e1

    CrossRef

  56. 56
    Rashmi R. Shah, Joel Morganroth, Evaluating the QT-Liability of a Drug during its Development, Pharmaceutical Medicine, 2008, 22, 3, 151

    CrossRef

  57. 57
    Caroline Améen, Raimund Strehl, Petter Björquist, Anders Lindahl, Johan Hyllner, Peter Sartipy, Human embryonic stem cells: Current technologies and emerging industrial applications, Critical Reviews in Oncology/Hematology, 2008, 65, 1, 54

    CrossRef

  58. 58
    Rashmi R. Shah, If a drug deemed ‘safe’ in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?, Pharmacology & Therapeutics, 2008, 119, 2, 215

    CrossRef

  59. 59
    Yasushi Orihashi, Points to Consider to Design the ‘Thorough QT/QTc Study’, Japanese Journal of Biometrics, 2008, 29, Special_Issue_1, S75

    CrossRef

  60. 60
    Yasushi Orihashi, Study Design and Statistical Evaluation of QT Prolongation, Japanese Journal of Biometrics, 2008, 29, Special_Issue_1, S61

    CrossRef

  61. 61
    Steve England, Voltage-gated sodium channels: the search for subtype-selective analgesics, Expert Opinion on Investigational Drugs, 2008, 17, 12, 1849

    CrossRef

  62. 62
    Frédéric Bouder, A Case Study of Long QT Regulation: A Regulatory Tennis Game Across the Atlantic, Journal of Risk Research, 2007, 10, 3, 385

    CrossRef

  63. 63
    Rashmi R Shah, Cardiac Repolarisation and Drug Regulation, Drug Safety, 2007, 30, 12, 1093

    CrossRef

  64. 64
    J Morganroth, Cardiac Repolarization and the Safety of New Drugs Defined by Electrocardiography, Clinical Pharmacology & Therapeutics, 2007, 81, 1
  65. 65
    Paul Kligfield, Benoit Tyl, Martine Maarek, Pierre Maison-Blanche, Magnitude, Mechanism, and Reproducibility of QT Interval Differences Between Superimposed Global and Individual Lead ECG Complexes, Annals of Noninvasive Electrocardiology, 2007, 12, 2
  66. 66
    José L. Méndez-Andino, John A. Wos, MCH-R1 antagonists: what is keeping most research programs away from the clinic?, Drug Discovery Today, 2007, 12, 21-22, 972

    CrossRef

  67. 67
    Peter Sartipy, Petter Björquist, Raimund Strehl, Johan Hyllner, The application of human embryonic stem cell technologies to drug discovery, Drug Discovery Today, 2007, 12, 17-18, 688

    CrossRef

  68. 68
    José L. Méndez-Andino, Anny-Odile Colson, Kenneth M. Meyers, Maria C. Mitchell, Karen Hodge, Jeremy M. Howard, Nicholas Kim, David C. Ackley, Jerry K. Holbert, Scott W. Mittelstadt, Martin E. Dowty, Cindy M. Obringer, Paula Suchanek, Ofer Reizes, X. Eric Hu, John A. Wos, The efficacy and cardiac evaluation of aminomethyl tetrahydronaphthalene ketopiperazines: A novel class of potent MCH-R1 antagonists, Bioorganic & Medicinal Chemistry, 2007, 15, 5, 2092

    CrossRef

  69. 69
    Rika EBANA, Norito TAKEMOTO, Masaaki MOCHII, Kuniko SAKURAI, Kimiyo IMAIZUMI, Junko YOSHIHARA, Tomiko SEKIGUCHI, Kuninobu YASUDA, Hiroaki FUJIWARA, Akihiro OHNISHI, Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2007, 38, 2, 97

    CrossRef

  70. 70
    Rashmi R Shah, Can pharmacogenetics help rescue drugs withdrawn from the market?, Pharmacogenomics, 2006, 7, 6, 889

    CrossRef

  71. 71
    Borje Darpo, Thierry Nebout, Philip T. Sager, Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline, The Journal of Clinical Pharmacology, 2006, 46, 5
  72. 72
    Janet B McGill, George L King, Paul H Berg, Karen L Price, Keri A Kles, Edward J Bastyr, David L Hyslop, Clinical safety of the selective PKC-β inhibitor, ruboxistaurin, Expert Opinion on Drug Safety, 2006, 5, 6, 835

    CrossRef

  73. 73
    William J. Crumb, Sean Ekins, R. Dustan Sarazan, James H. Wikel, Steven A. Wrighton, Christopher Carlson, Charles M. Beasley, Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis, Pharmaceutical Research, 2006, 23, 6, 1133

    CrossRef

  74. 74
    Laurie A. Hanson, Alan S. Bass, Gary Gintant, Scott Mittelstadt, David Rampe, Karluss Thomas, ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation, Journal of Pharmacological and Toxicological Methods, 2006, 54, 2, 116

    CrossRef

  75. 75
    Borje Darpo, Marilyn Agin, David J. Kazierad, Gary Layton, Gary Muirhead, Peter Gray, Diane K. Jorkasky, Man Versus Machine: Is There an Optimal Method for QT Measurements in Thorough QT Studies?, The Journal of Clinical Pharmacology, 2006, 46, 6
  76. 76
    Paul Kligfield, E. William Hancock, Eric D. Helfenbein, Emilie J. Dawson, Melynda A. Cook, James M. Lindauer, Sophia H. Zhou, Joel Xue, Relation of QT Interval Measurements to Evolving Automated Algorithms from Different Manufacturers of Electrocardiographs, The American Journal of Cardiology, 2006, 98, 1, 88

    CrossRef

  77. 77
    Pentti M. Rautaharju, A farewell to QT dispersion, Journal of Electrocardiology, 2005, 38, 1, 7

    CrossRef

  78. 78
    Martin Traebert, Berengere Dumotier, Antimalarial drugs: QT prolongation and cardiac arrhythmias, Expert Opinion on Drug Safety, 2005, 4, 3, 421

    CrossRef

  79. 79
    P. Chaikin, M. S. Gillen, M. Malik, H. Pentikis, G. R. Rhodes, D. J. Roberts, Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects, British Journal of Clinical Pharmacology, 2005, 59, 3
  80. 80
    Gayle Provan, Andrea Stanton, Anthea Sutton, Ann Rankin-Burkart, Sarra K. Laycock, Development of a surgical approach for telemetering guinea pigs as a model for screening QT interval effects, Journal of Pharmacological and Toxicological Methods, 2005, 52, 2, 223

    CrossRef

  81. 81
    Johannes Schneider, Renate Hauser, Jens-Otto Andreas, Klaus Linz, Ulrich Jahnel, Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs, European Journal of Pharmacology, 2005, 512, 1, 53

    CrossRef

  82. 82
    Rashmi R. Shah, Drug-induced QT dispersion: does it predict the risk of torsade de pointes?, Journal of Electrocardiology, 2005, 38, 1, 10

    CrossRef

  83. 83
    Rashmi R Shah, Drugs, QT Interval Prolongation and ICH E14, Drug Safety, 2005, 28, 2, 115

    CrossRef

  84. 84
    Rashmi R Shah, Drugs, QTc Interval Prolongation and Final ICH E14 Guideline, Drug Safety, 2005, 28, 11, 1009

    CrossRef

  85. 85
    Charles R. Partridge, Charles D. Johnson, Kenneth S. Ramos, In vitro models to evaluate acute and chronic injury to the heart and vascular systems, Toxicology in Vitro, 2005, 19, 5, 631

    CrossRef

  86. 86
    Radoslaw Owczuk, Wioletta Sawicka, Magdalena A. Wujtewicz, Aleksandra Kawecka, Jerzy Lasek, Maria Wujtewicz, Influence of Spinal Anesthesia on Corrected QT Interval, Regional Anesthesia and Pain Medicine, 2005, 30, 6, 548

    CrossRef

  87. 87
    Rashmi R Shah, Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules, Expert Opinion on Drug Safety, 2005, 4, 1, 103

    CrossRef

  88. 88
    R. R. Shah, Pharmacogenetics in drug regulation: promise, potential and pitfalls, Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1460, 1617

    CrossRef

  89. 89
    Motohiro SHIOTANI, Takuma HARADA, Junko ABE, Yasufusa SAWADA, Keitaro HASHIMOTO, Yoshimasa HAMADA, Ikuo HORII, PRACTICAL APPLICATION OF GUINEA PIG TELEMETRY SYSTEM FOR QT EVALUATION, The Journal of Toxicological Sciences, 2005, 30, 3, 239

    CrossRef

  90. 90
    Beny Charbit, Pierre Albaladejo, Christian Funck-Brentano, Mathieu Legrand, Emmanuel Samain, Jean Marty, Prolongation of QTc Interval after Postoperative Nausea and Vomiting Treatment by Droperidol or Ondansetron, Anesthesiology, 2005, 102, 6, 1094

    CrossRef

  91. 91
    Rashmi R. Shah, Luc M. Hondeghem, Refining detection of drug-induced proarrhythmia: QT interval and TRIaD, Heart Rhythm, 2005, 2, 7, 758

    CrossRef

  92. 92
    R. Ridruejo Sáez, B. Zalba Etayo, E. Civeira Murillo, N. Montes Castro, J. Munárriz Hinojosa, Síndrome de QT largo adquirido en pacientes ingresados en UCI, Medicina Intensiva, 2005, 29, 7, 379

    CrossRef

  93. 93
    Charles M. Beasley, Malcolm I. Mitchell, Alex A. Dmitrienko, Jeffrey T. Emmick, Wei Shen, Timothy M. Costigan, Alun W. Bedding, Michael A. Turik, Arash Bakhtyari, Margaret R. Warner, Jeremy N. Ruskin, Louis R. Cantilena, Robert A. Kloner, The Combined Use of Ibutilide as an Active Control With Intensive Electrocardiographic Sampling and Signal Averaging as a Sensitive Method to Assess the Effects of Tadalafil on the Human QT Interval, Journal of the American College of Cardiology, 2005, 46, 4, 678

    CrossRef

  94. 94
    Keith Finlayson, Harry J. Witchel, James McCulloch, John Sharkey, Acquired QT interval prolongation and HERG: implications for drug discovery and development, European Journal of Pharmacology, 2004, 500, 1-3, 129

    CrossRef

  95. 95
    Sean Hennessy, Warren B. Bilker, Jill S. Knauss, Stephen E. Kimmel, David J. Margolis, Mary F. Morrison, Robert F. Reynolds, Dale B. Glasser, Brian L. Strom, Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol, British Journal of Clinical Pharmacology, 2004, 58, 1
  96. 96
    CHRISTINA DAVIE, JEAN PIERRE-VALENTIN, CHRIS POLLARD, NICK STANDEN, JOHN MITCHESON, PAUL ALEXANDER, BOB THONG, Comparative Pharmacology of Guinea Pig Cardiac Myocyte and Cloned hERG (IKr) Channel, Journal of Cardiovascular Electrophysiology, 2004, 15, 11
  97. 97
    Nkechi E. Azie, Gregory Adams, Borje Darpo, Steven F. Francom, Emery C. Polasek, Joy M. Wisser, Joseph C. Fleishaker, Comparing Methods of Measurement for Detecting Drug-Induced Changes in the QT Interval: Implications for Thoroughly Conducted ECG Studies, Annals of Noninvasive Electrocardiology, 2004, 9, 2
  98. 98
    Rikke Kaae, Lone Agertoft, Sören Pedersen, S Lennart Nordvall, Christophe Pedroletti, Thomas Bengtsson, Ingegerd Johannes-Hellberg, Johan Rosenborg, Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6–11 years-old than cumulative high doses of inhaled terbutaline, British Journal of Clinical Pharmacology, 2004, 58, 4
  99. You have free access to this content99
    Nenad Sarapa, Joel Morganroth, Jean-Philippe Couderc, Steven F. Francom, Borje Darpo, Joseph C. Fleishaker, Janet D. McEnroe, William T. Chen, Wojciech Zareba, Arthur J. Moss, Electrocardiographic Identification of Drug-Induced QT Prolongation: Assessment by Different Recording and Measurement Methods, Annals of Noninvasive Electrocardiology, 2004, 9, 1
  100. 100
    S. P. Lee, L. Yeoh, N. D. Harris, C. M. Davies, R. T. Robinson, A. Leathard, C. Newman, I. A. Macdonald, S. R. Heller, Influence of Autonomic Neuropathy on QTc Interval Lengthening During Hypoglycemia in Type 1 Diabetes, Diabetes, 2004, 53, 6, 1535

    CrossRef

  101. 101
    Rashmi R Shah, Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes, Drug Safety, 2004, 27, 3, 145

    CrossRef

  102. 102
    Marek Malik, Assessment of T-Wave Morphology, Mayo Clinic Proceedings, 2003, 78, 1, 18

    CrossRef

  103. 103
    Nenad Sarapa, Margaret R. Britto, Barbara Cotton, Steven R. Cox, Steven F. Francom, Na Jin, Emery D. Polasek, Stephen M. Sainati, Sharon L. Crosby-Sessoms, Joseph C. Fleishaker, Valdecoxib, a COX-2-Specific Inhibitor, Does Not Affect Cardiac Repolarization, The Journal of Clinical Pharmacology, 2003, 43, 9
  104. 104
    Preclinical Antecedents to Early Human Clinical Trials,
  105. 105
    Alberto Lodola, Risk Management,
  106. 106
    Brian L. Strom, What is Pharmacoepidemiology?,